A PREDICTIVE AND COMPARATIVE STUDY VIA VIRAL AND BIOCHEMICAL MEASUREMENTS FOR RESPONDERS AND NON-RESPONDERS EGYPTIAN HEPATITIS C PATIENTS TO DACLATASVIR PLUS SOFOSBUVIR THERAPY

Serum markers in monitoring the outcome of Sofosbuvir-based treatments in HCV genotype 4 Egyptian patients

INTERLEUKIN 28B GENE POLYMORPHISMS AS A PREDICTOR OF TREATMENT RESPONSE IN EGYPTIANS WITH CHRONIC HEPATITIS C.

MOLECULAR MARKERS PREDICTING THE EFFICACY OF INTERFERON-BASED THERAPIES IN PATIENTS WITH CHRONIC HEPATITIS C

Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon in Management of Egyptian Chronic Hepatitis C Patients

Biochemical Hepatic Changes in Chronic Hepatitis C Patients Induced by Sofosbuvir and Daclatasvir with or without Ribavirin Regimens

Biochemical evaluation of the combination of Pegylated IFN-α2b and Ribavarin therapy of Egyptian patients suffering from Hepatitis C Virus

Biochemical markers and physiological functions in Egyptian patients with hepatitis C virus

Biochemical study on the response to HCV therapy (Velpatasvir containing regimen), (vosevi) among adult patients’ non-responders to treatment in Fayoum Egypt

Studying the Kynurenine, Some Hematological and Biochemical Changes on Egyptian Patients with Chronic Hepatitis C During and After Treatment with Sofosbuvir